Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVac®?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration ScheduleResourcesResourcesMaterialsVideosOrder TicoVac®
Prescribing Information Indication Patient Site
What is TBE?What is Tick-Borne Encephalitis Virus (TBEV) & How is it Transmitted?

The TBE virus is a rare, zoonotic arbovirus traditionally endemic to Central and Eastern Europe, as well as Russia, but has also been reported in Eastern Asian countries.1 The virus itself is a member of the Flavivirus family, which also includes viruses that can cause dengue fever, yellow fever, and Japanese encephalitis.2

Infection of TBE virus by ticks can occur in any place where ticks are endemic, such as wooded areas, parks, gardens, forests, or other outdoor locations.3

It Can Take Just One Bite.

When a tick acting as a TBE vector bites humans or animals, there is a significant risk that those organisms will become infected with the TBE virus.4

Transmission of the virus can also occur through the consumption of unpasteurized dairy products that have been contaminated with the TBE virus.4 TBE severity may be associated with viral subtype.1 TBE virus subtypes may cause different clinical characteristics of TBE and have different mortality rates.1,5

Infections from either of the subtypes have been shown to attack the Central Nervous Systems (CNS), leading to potentially severe or, on rare occasion, fatal outcomes.6

There is no cure or treatment for TBE.7,8 Patients infected are only able to manage their symptoms through various treatment methods.7,8​​​​​​​

References:Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect Dis. 1999;28(4):882-890. doi: 10.1086/515195Bogovic P, Strle F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases. 2015;3(5):430-441. doi:10.12998/wjcc.v3.i5.430World Health Organization. Tick-borne encephalitis. Accessed February 9, 2022. https://www.who.int/health-topics/tick-borne-encephalitis.European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE). Accessed February 9, 2022. https://www.ecdc.europa.eu/en/tick-borne-encephalitis/facts/factsheet.Barp N, Trentini A, Di Nuzzo M, Mondardini V, Francavilla E, Contini C. Clinical and laboratory findings in tick-borne encephalitis virus infection. Parasite Epidemiol Control. 2020;10:e00160. doi:10.1016/j.parepi.2020.e00160Chrdle A, Chmelík V, Růžek D. Tick-borne encephalitis: What travelers should know when visiting an endemic country. Hum Vaccin Immunother. 2016;12(10):2694-2699. doi:10.1080/21645515.2016.1218098TicoVac® (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.Dobler G, Erber W, Bröker M, Schmitt HJ. The TBE Book. 4th ed. Global Health Press; 2021. ​​​​​​​Centers for Disease Control and Prevention. Tickborne Encephalitis. Travelers’ Health. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/diseases/tickborne-encephalitis.
SYMPTOMS & RISK FACTORS

Travelers spending time in wooded or grassy areas in many parts of Europe and Asia may be at risk for infection with tick-borne encephalitis virus (TBEV).9

​​​​​Go to symptoms & risk factors
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-TCV-USA-0213
INDICATION AND USAGE TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
IMPORTANT SAFETY INFORMATION
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Indication TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
Important Safety Information
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. Please see full prescribing information for TicoVac® here. Indication
TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367